Septerna Competitors
| SEPN Stock | 28.30 2.00 6.60% |
Septerna Common vs Arbutus Biopharma Correlation
Average diversification
The correlation between Septerna Common Stock and ABUS is 0.11 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Septerna Common Stock and ABUS in the same portfolio, assuming nothing else is changed.
Moving against Septerna Stock
| 0.61 | NXS | Next Science Earnings Call This Week | PairCorr |
| 0.37 | KG | Kestrel Group Symbol Change | PairCorr |
| 0.37 | HCM | HUTCHMED China | PairCorr |
Septerna Common Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Septerna Common and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Septerna and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Septerna Common Stock does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Septerna Stock performing well and Septerna Common Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Septerna Common's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | 2.81 | (0.01) | (0.01) | 0.02 | 3.07 | 6.05 | 19.25 | |||
| TNGX | 3.59 | 0.84 | 0.23 | 2.85 | 3.01 | 11.29 | 31.20 | |||
| FTRE | 3.62 | (0.13) | (0.01) | 0.00 | 5.15 | 7.63 | 29.57 | |||
| PRME | 3.93 | (0.05) | (0.01) | 0.01 | 4.39 | 10.19 | 25.37 | |||
| KURA | 2.84 | (0.32) | 0.00 | (0.31) | 0.00 | 5.01 | 22.83 | |||
| EYPT | 3.46 | 0.38 | 0.09 | (1.87) | 3.29 | 8.15 | 23.49 | |||
| PROK | 3.72 | (0.32) | 0.00 | (0.12) | 0.00 | 6.82 | 22.38 | |||
| MRVI | 2.81 | (0.12) | 0.00 | (0.04) | 0.00 | 8.38 | 22.00 | |||
| NRIX | 3.06 | 0.42 | 0.12 | 0.59 | 2.97 | 7.07 | 27.63 | |||
| ABUS | 2.60 | (0.23) | 0.00 | (0.15) | 0.00 | 5.47 | 20.16 |
Cross Equities Net Income Analysis
Compare Septerna Common Stock and related stocks such as Bicara Therapeutics, Tango Therapeutics, and Fortrea Holdings Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (52 M) | (68 M) | (61.2 M) | (64.3 M) |
| TNGX | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (52 M) | (58.2 M) | (108.2 M) | (101.7 M) | (130.3 M) | (117.3 M) | (123.1 M) |
| FTRE | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | 98 M | 186.2 M | (25.2 M) | (328.5 M) | (295.6 M) | (280.9 M) |
| KURA | (33.6 K) | (22.4 K) | (27 K) | (27.3 K) | (11 M) | (22.6 M) | (27.6 M) | (35.4 M) | (60.4 M) | (63.1 M) | (89.6 M) | (130.5 M) | (135.8 M) | (152.6 M) | (174 M) | (156.6 M) | (148.8 M) |
| EYPT | (2.3 M) | (8.6 M) | (24.8 M) | (11.9 M) | (13.4 M) | 6.3 M | (21.5 M) | (18.5 M) | (53.2 M) | (56.8 M) | (45.4 M) | (58.4 M) | (102.3 M) | (70.8 M) | (130.9 M) | (117.8 M) | (111.9 M) |
| PROK | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (26.7 M) | (55.1 M) | (108 M) | (35.5 M) | (61.2 M) | (70.4 M) | (73.9 M) |
| MRVI | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (8.5 M) | 76.9 M | 182 M | 220.2 M | (119 M) | (144.8 M) | (130.4 M) | (123.8 M) |
| NRIX | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (21.7 M) | (43.2 M) | (117.2 M) | (166 M) | (143.9 M) | (193.6 M) | (264.5 M) | (238 M) | (226.1 M) |
| ABUS | (8.8 M) | (9.7 M) | 29.9 M | (14.1 M) | (38.8 M) | (61.1 M) | (384.1 M) | (84.4 M) | (57.1 M) | (153.7 M) | (63.7 M) | (76.2 M) | (69.5 M) | (72.8 M) | (69.9 M) | (62.9 M) | (66.1 M) |
Septerna Common Stock and related stocks such as Bicara Therapeutics, Tango Therapeutics, and Fortrea Holdings Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Septerna Common Stock financial statement analysis. It represents the amount of money remaining after all of Septerna Common Stock operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Septerna Common Competitive Analysis
The better you understand Septerna Common competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Septerna Common's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Septerna Common's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Septerna Common Competition Performance Charts
Five steps to successful analysis of Septerna Common Competition
Septerna Common's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Septerna Common Stock in relation to its competition. Septerna Common's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Septerna Common in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Septerna Common's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Septerna Common Stock, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Septerna Common position
In addition to having Septerna Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Farming Thematic Idea Now
Farming
Companies producing farming products and providing services for farmers. The Farming theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Farming Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Septerna Common Correlation with its peers. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Will Pharmaceuticals sector continue expanding? Could Septerna diversify its offerings? Factors like these will boost the valuation of Septerna Common. If investors know Septerna will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Septerna Common data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.90) | Revenue Per Share | Quarterly Revenue Growth 121.131 | Return On Assets | Return On Equity |
The market value of Septerna Common Stock is measured differently than its book value, which is the value of Septerna that is recorded on the company's balance sheet. Investors also form their own opinion of Septerna Common's value that differs from its market value or its book value, called intrinsic value, which is Septerna Common's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Septerna Common's market value can be influenced by many factors that don't directly affect Septerna Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Septerna Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Septerna Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Septerna Common's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.